Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.

BRIEF-Novo Nordisk Says People With Type 2 Diabetes Who Were Increased To Semaglutide 2 Mg Were more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide

Novo Nordisk - Semaglutide 2 Mg Matches Tirzepatide for Hba1c <7% and Outperforms for ≥5% Weight Loss at 1 Year

LIVE MARKETS-GLP-1 obesity, diabetes drug market to hit $150 billion in 2030, TD Cowen says

Veru Enters Supply Agreement With Novo Nordisk for Obesity Study; Shares Surge

Veru pact with Novo ‘significant event,’ says Canaccord

Veru announces clinical supply agreement with Novo Nordisk

Novo Nordisk Expands Obesity Pipeline With New First‑in‑Human Trial for NNC0113-5840

Novo Nordisk (0QIU) Gets a Hold from Goldman Sachs

Novo Nordisk A/S Stock Falls Wednesday, Underperforms Market

Dow Jones Top Company Headlines at 7 AM ET: Baidu Sees AI, Chip Business Driving Healthy Revenue Growth | Zara ...

Novo Nordisk's UAE Wegovy Pill Launch an Important Step -- Market Talk

Novo Nordisk Launches Wegovy Oral Weight-Loss Drug in UAE, Its First Market Outside the United States

EXCLUSIVE-Cigna drops coverage of GLP-1 obesity drugs for its own employees

Novo Nordisk Partners With Metabolic for Early Access to Oral Wegovy in UAE

Novo Nordisk A/S Stock Falls Monday, Underperforms Market

Moderately bullish activity in Novo Nordisk with shares down 2.99%

Cboe data suggests bullish flow in Novo Nordisk with shareslittle changed

Novo Nordisk’s CagriSema Trial Puts Next-Generation Obesity Strategy in Focus